Document resource
Without timely and appropriate treatment, hepatitis B virus (HBV) infection can progress to liver fibrosis, cirrhosis or hepatocellular carcinoma (HCC), contributing significantly to global liver-related morbidity and mortality. 1 Africa carries the highest global HBV burden, with an estimated 65 million people infected in 2022, and 25% are under 20 years of age.2 While the regional average prevalence is 5.8%,1 18 African countries have exceeded 8% HBV prevalence. 3 Vertical and early childhood HBV transmission are common, carrying chronicity risks of up to 90% and 30%–60%, respectively, and can lead to severe complications such as cirrhosis and HCC. Survival outcomes for HCC are particularly poor in Africa, averaging only 1.5 months post-diagnosis.2